In a groundbreaking collaboration, abc biopply AG, the Zurich University of Applied Sciences (ZHAW), and the University of Zurich (UZH) have joined forces to develop a next-generation 3D multi-organoid in vitro platform designed to transform drug development and personalized cancer therapy. The initiative is supported by the Swiss national funding agency Innosuisse.